Figure 3 Percentage changes (average (SE)) in regional myocardial blood flow (MBF) at rest and during dipyridamole (Dip) infusion, as well as in regional coronary flow reserve (CFR), from enrolment to 6 months of treatment, are represented for patients treated with placebo (group 1) or with carvedilol (group 2) in regions with (Dip+) or without (Dip−) defects at enrolment. The two groups significantly differed in analysis of variance. Directional response of maximal MBF and CFR to carvedilol was similar in Dip+ or Dip– regions. By contrast, resting MBF actually decreased after carvedilol in Dip+ regions, whereas it increased in Dip– regions. Accordingly, CFR‐positive changes induced by carvedilol were more evident in Dip+ regions (See section Discussion).